GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » EV-to-Revenue
中文

BB Biotech AG (XSWX:BION) EV-to-Revenue : -13.84 (As of Apr. 25, 2024)


View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BB Biotech AG's enterprise value is CHF2,577.77 Mil. BB Biotech AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-186.30 Mil. Therefore, BB Biotech AG's EV-to-Revenue for today is -13.84.

The historical rank and industry rank for BB Biotech AG's EV-to-Revenue or its related term are showing as below:

XSWX:BION' s EV-to-Revenue Range Over the Past 10 Years
Min: -56.27   Med: 2.95   Max: 57.27
Current: -13.84

During the past 13 years, the highest EV-to-Revenue of BB Biotech AG was 57.27. The lowest was -56.27. And the median was 2.95.

XSWX:BION's EV-to-Revenue is ranked worse than
100% of 1032 companies
in the Biotechnology industry
Industry Median: 7.64 vs XSWX:BION: -13.84

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-25), BB Biotech AG's stock price is CHF41.45. BB Biotech AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-3.40. Therefore, BB Biotech AG's PS Ratio for today is .


BB Biotech AG EV-to-Revenue Historical Data

The historical data trend for BB Biotech AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG EV-to-Revenue Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.12 5.96 -7.70 -11.08 -19.22

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.08 -13.38 -55.06 -11.58 -19.22

Competitive Comparison of BB Biotech AG's EV-to-Revenue

For the Biotechnology subindustry, BB Biotech AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's EV-to-Revenue falls into.



BB Biotech AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BB Biotech AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2577.767/-186.303
=-13.84

BB Biotech AG's current Enterprise Value is CHF2,577.77 Mil.
BB Biotech AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-186.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BB Biotech AG  (XSWX:BION) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BB Biotech AG's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=41.45/-3.403
=

BB Biotech AG's share price for today is CHF41.45.
BB Biotech AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-3.40.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BB Biotech AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (XSWX:BION) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Executives
Prof. Dr. Mads Krogsgaard Thomsen Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines